Study Stopped
Endo determined to discontinue its registries and the CURVE registry enrollment has been closed.
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
CURVE-PD
Clinical Understanding Through Real-world Data to Validate Effectiveness of Treatments in Peyronie's Disease
1 other identifier
observational
29
1 country
7
Brief Summary
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2023
Shorter than P25 for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 15, 2023
CompletedFirst Posted
Study publicly available on registry
May 24, 2023
CompletedStudy Start
First participant enrolled
June 20, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 26, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 26, 2024
CompletedApril 16, 2024
April 1, 2024
8 months
May 15, 2023
April 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants Receiving Each Treatment Type for PD
Up to 12 months
Secondary Outcomes (6)
Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score
Up to 12 months
Change from Baseline in International Index of Erectile Function (IIEF) Score
Up to 12 months
Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score
Up to 12 months
Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score
Up to 12 months
Participant Satisfaction Questionnaire
Up to 12 months
- +1 more secondary outcomes
Eligibility Criteria
Participants with a confirmed diagnosis of PD will be enrolled in the United States.
You may qualify if:
- Any adult with a confirmed clinical diagnosis of PD.
- Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
- Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
- Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment.
- Able to participate in English based registry.
You may not qualify if:
- Not having a clinical diagnosis of PD.
- Age less than 18 years.
- Do not provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Endo Pharmaceuticals Clinical Site 2
San Diego, California, 92120, United States
Endo Pharmaceuticals Clinical Site 3
Miami, Florida, 33136, United States
Endo Pharmaceuticals Clinical Site 6
Greenwood, Indiana, 46143, United States
Endo Pharmaceuticals Clinical Site 5
Lansing, Michigan, 48912, United States
Endo Pharmaceuticals Clinical Site 7
Gahanna, Ohio, 43230, United States
Endo Pharmaceuticals Clinical Site 4
Houston, Texas, 77030, United States
Endo Pharmaceuticals Clinical Site 1
Orem, Utah, 84057, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Information
Endo Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 1 Year
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2023
First Posted
May 24, 2023
Study Start
June 20, 2023
Primary Completion
February 26, 2024
Study Completion
February 26, 2024
Last Updated
April 16, 2024
Record last verified: 2024-04